| 英文别名 |
DCC-2618;N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- yl]-2-fluorophenyl}-N'-phenylurea;Ripretinib;Ripretinib free base;9XW757O13D;Ripretinib (USAN);Ripretinib [USAN];1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea;Q;Ripretinib (DCC-2618);BDBM50609506;DCC 2618;DCC2618;KIT/PDGFR inhibitor;Ripretinib;Ripretinib (DCC-2618)?;RIPRETINIB [WHO-DD];DB14840;1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea;3-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl}-1-phenylurea;HY-112306;D11353;RIPRETINIB [MI];SCHEMBL14999718;KIT/PDGFR Inhibitor DCC-2618;AC-36722;EX-A4883;MS-29471;3-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-1-phenylurea;qinlock;C24H21BrFN5O2;EN300-22895298;Quinlock;s8757;RIPRETINIB [ORANGE BOOK];Qinlock (TN);1442472-39-0;Ripretinib; Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-phenyl-; N-[4-Bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-phenylurea; 1-[4-Bromo-5-[1-ethyl-7-(methyla;ripretinibum;BCP29218;RIPRETINIB [INN];Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-;N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea;AKOS040759418;UNII-9XW757O13D;CS-0044835;AT18473;1-N'-(2,5-difluoro-4-(2-(1-methylpyrazol-4-yl)pyridin-4-yl)oxyphenyl)-1-N'-phenylcyclopropane-1,1-dicarboxamide;1442472-39-0 (free base);DA-52358;DTXSID201027956;Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6- naphthyridin-3-yl]-2-fluorophenyl]-N'-phenyl-39-0;CHEMBL4216467;DCC2618;GLXC-15506;GTPL9175 |
微信公众号
客服
C1%3dCC2%3dC(N1)C%3dCC%3dN2)
Cl)F)
